Who Supplies Itraconazole to India from BULGARIA

To import finished pharmaceutical formulations containing Itraconazole into India, the foreign manufacturer must obtain an Import Registration and License from the Central Drugs Standard Control Organization (CDSCO). This process involves submitting an application along with necessary documents, including a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration timeline varies but typically ranges from 6 to 12 months, depending on the completeness of the application and compliance with regulatory requirements. Form CT-20/40/41 is used for registration, and the Directorate General of Foreign Trade (DGFT) import license is also required. The Drug Controller General of India (DCGI) approval is mandatory for all imported drugs. A No Objection Certificate (NOC) from the Ministry of Health and Family Welfare may be necessary for certain products. Specific requirements for Itraconazole formulations under HS Code 30049099 include detailed product information, manufacturing process details, and evidence of safety and efficacy.

Imported Itraconazole formulations must undergo quality testing at CDSCO-approved laboratories in India. Batch-wise testing is mandatory, and a Certificate of Analysis (CoA) is required for each batch. Stability data must comply with International Council for Harmonisation (ICH) guidelines, specifically for Zone IV conditions, to ensure product stability in India's climate. The formulations must meet the standards set by the Indian Pharmacopoeia. Upon arrival, customs drug inspectors conduct port inspections to verify compliance with these requirements.

In April 2025, the CDSCO introduced new regulations mandating import registration and licenses for all imported medicines to prevent the sale of unapproved or illegal drugs in the Indian market. This policy requires foreign manufacturers to obtain CDSCO approval before distributing their products domestically. The Production-Linked Incentive (PLI) scheme, introduced in 2020, aims to boost domestic manufacturing and may impact the import of finished formulations, including Itraconazole. Bilateral agreements between India and Bulgaria have facilitated smoother trade relations, but specific details regarding mutual Good Manufacturing Practice (GMP) recognition are currently unavailable.

India imports finished Itraconazole formulations to meet the demand for patented or branded products, specialized dosage forms, and formulations not produced domestically. The domestic capacity for manufacturing Itraconazole formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Itraconazole formulations in India is substantial, with a total export market of $27.4 million across 285 exporters to 123 countries.

The Basic Customs Duty (BCD) for Itraconazole formulations under HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable. Additionally, a Social Welfare Surcharge (SWS) of 10% is levied. The total landed duty, including all applicable taxes and surcharges, is approximately 23.536% of the Cost, Insurance, and Freight (CIF) value.

India sources Itraconazole formulations from Bulgaria due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Bulgaria's pharmaceutical industry is known for its adherence to international quality standards, making it a competitive supplier. Other major suppliers include China, Germany, and the United States. Bulgaria's share in India's Itraconazole import market is currently limited, but the quality and specialization of its products offer a competitive edge.

India imports Itraconazole formulations from Bulgaria due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. Bulgaria's pharmaceutical industry is known for its adherence to international quality standards, making it a competitive supplier. Specific formulations supplied by Bulgaria that India does not manufacture domestically include certain specialized dosage forms and combination therapies.

Compared to other sources like China, Germany, and the United States, Bulgaria offers competitive pricing and high-quality products. While China may offer lower prices, concerns about quality and regulatory compliance can be a drawback. Germany and the United States provide high-quality products but at higher prices. Bulgaria's unique advantage lies in its balance of quality and cost-effectiveness, making it an attractive sourcing option for Indian importers.

Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in the Bulgaria to India corridor. To mitigate risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letter of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with regulatory standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Submit Form CT-20/40/41 for registration of the product